Different doses of gabapentin formulations for postherpetic neuralgia: A systematical review and meta-analysis of randomized controlled trials

Journal of Dermatological Treatment

Volumn 28, Issue 1, 2017, Pages 65-77

  Wang, Juan ^a   Zhu, Yuyou ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

efficacy; Gabapentin; meta analysis; postherpetic neuralgia; safety

Indexed keywords

GABAPENTIN; 1-(((ALPHA-ISOBUTANOYLOXYETHOXY)CARBONYL)AMINOMETHYL)-1-CYCLOHEXANEACETIC ACID; 4 AMINOBUTYRIC ACID; AMINE; ANALGESIC AGENT; CARBAMIC ACID DERIVATIVE; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE;

ADVERSE DRUG REACTION; AVERAGE DAILY PAIN SCORE; CLINICIAN GLOBAL IMPRESSION OF CHANGE; DIZZINESS; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; META ANALYSIS; PAIN INTENSITY; PATIENT GLOBAL IMPRESSION OF CHANGE; PERIPHERAL EDEMA; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SHORT FORM 36; SLEEP INTERFERENCE SCORE; SOMNOLENCE; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; NEURALGIA, POSTHERPETIC;

AMINES; ANALGESICS; CARBAMATES; CYCLOHEXANECARBOXYLIC ACIDS; GAMMA-AMINOBUTYRIC ACID; HUMANS; NEURALGIA, POSTHERPETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84994135525     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2016.1163315     Document Type: Review

References (27)

1. Bowsher D., The management of postherpetic neuralgia. Postgrad Med J. 1997;73:623–9.
2. Choo PW, Galil K, Donahue JG, et al. Risk factors for postherpetic neuralgia. Arch Intern Med. 1997;157:1217–24.
3. Lukas K, Edte A, Bertrand I., The impact of herpes zoster and post-herpetic neuralgia on quality of life:patient-reported outcomes in six European countries. Z Gesundh Wiss. 2012;20:441–51.
4. Gnann JW, Whitley RJ., Clinical practice. Herpes zoster. N Engl J Med. 2002;347:340–6.
5. Johnson RW, Wasner G, Saddier P, Baron R., Postherpetic neuralgia:epidemiology, pathophysiology and management. Expert Rev Neurother. 2007;7:1581–95.
6. Hall GC, Carroll D, Parry D, McQuay HJ., Epidemiology and treatment of neuropathic pain:the UK primary care perspective. Pain. 2006;122:156–62.
7. Goa KL, Sorkin EM., Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs. 1993;46:409–27.
8. Stewart BH, Kugler AR, Thompson PR, Bockbrader HN., A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res. 1993;10:276–81.
9. Backonja M, Glanzman RL., Gabapentin dosing for neuropathic pain:evidence from randomized, placebo-controlled clinical trials. Clin Ther. 2003;25:81–104.
10. Gordi T, Hou E, Kasichayanula S, Berner B., Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive-extended-release and immediate-release tablets:a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects. Clin Ther. 2008;30:909–16.
11. Chen C, Cowles VE, Sweeney M., The intestinal absorption mechanism of gabapentin makes it appropriate for gastroretentive delivery. Curr Clin Pharmacol. 2013;8:67–72.
12. Irving G, Jensen M, Cramer M, et al. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia results of a double-blind, randomized, placebo-controlled clinical trial. Clin J Pain. 2009;25:185–92.
13. Wallace MS, Irving G, Cowles VE. Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia:a randomized, double-blind, placebo-controlled, multicentre study. Clin Drug Invest. 2010;30:765–76.
14. Cundy K, Branch R, Chernov-Rogan T, et al. XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug:I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther. 2004;311:315–23.
15. Cundy KC, Annamalai T, Bu L, et al. XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug:II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther. 2004;311:324–33.
16. Backonja MM, Canafax DM, Cundy KC., Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin. Pain Med. 2011;12:1098–108.
17. Zhang L, Rainka M, Freeman R, et al. A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of gabapentin enacarbil in subjects with neuropathic pain associated with postherpetic neuralgia (PXN110748). J Pain. 2013;14:590–603.
18. Meng FY, Zhang LC, Liu Y, et al. Efficacy and safety of gabapentin for treatment of postherpetic neuralgia:a meta-analysis of randomized controlled trials. Minerva Anestesiol. 2014;80:556–67.
19. Fan H, Yu W, Zhang Q, et al. Efficacy and safety of gabapentin 1800 mg treatment for post-herpetic neuralgia:a meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2014;39:334–42.
20. Stacey BR, Glanzman RL., Use of gabapentin for postherpetic neuralgia:results of two randomized, placebo-controlled studies. Clin Ther. 2003;25:2597–608.
21. Higgins JPT, Green S., Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration; 2011. Available from:http:\\www.cochrane-handbook.org. Accessed March 2011.
22. Rice AS, Maton S., Gabapentin in postherpetic neuralgia:a randomised, double blind, placebo controlled study. Pain. 2001;94:215–24.
23. Rowbotham M, Harden N, Stacey B, et al. Grp GPNS. Gabapentin for the treatment of postherpetic neuralgia:a randomized controlled trial. JAMA. 1998;280:1837–42.
24. Sang CN, Sathyanarayana R, Sweeney M, Investigators D-S., Gastroretentive gabapentin (G-GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN). Clin J Pain. 2013;29:281–8.
25. Chen C., Meta-analyses of dose-exposure relationships for gabapentin following oral administration of gabapentin and gabapentin enacarbil. Eur J Clin Pharmacol. 2013;69:1809–17.
26. Gilbody S, Bower P, Torgerson D, Richards D., Cluster randomized trials produced similar results to individually randomized trials in a meta-analysis of enhanced care for depression. J Clin Epidemiol. 2008;61:160–8.
27. Bland JM., Cluster randomised trials in the medical literature:two bibliometric surveys. BMC Med Res Methodol. 2004;4:21.